https://scholars.lib.ntu.edu.tw/handle/123456789/503709
標題: | MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multi-centre, open-label, phase I trial | 作者: | Sarker, Debashis Plummer, Ruth Meyer, Tim Sodergren, Mikael Basu, Bristi Chee, Cheng Ean KAI-WEN HUANG Palmer, Daniel H Ma, Yuk Ting Evans, T R Jeffry Spalding, Duncan Rc Pai, Madhava Sharma, Rohini Pinato, David J Spicer, James Hunter, Sarah Kwatra, Vineet Nicholls, Joanna P Collin, David Nutbrown, Robert Glenny, Helen Fairbairn, Sonia Reebye, Vikash Voutila, Jon Dorman, Stephanie Andrikakou, Pinelopi Lloyd, Peter Felstead, Steve Vasara, Jenni Habib, Robert Wood, Chris Sætrom, Pål Huber, Hans E Blakey, David C Rossi, John J Habib, Nagy |
公開日期: | 1-五月-2020 | 來源出版物: | Clinical cancer research : an official journal of the American Association for Cancer Research | 摘要: | Transcription factor C/EBP-α (CCAAT/enhancer-binding protein alpha) acts as a master regulator of hepatic and myeloid functions and multiple oncogenic processes. MTL-CEBPA is a first-in-class small activating RNA oligonucleotide drug which up-regulates C/EBP-α. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/503709 | ISSN: | 1078-0432 | DOI: | 10.1158/1078-0432.CCR-20-0414 | SDG/關鍵字: | antineoplastic agent; CCAAT enhancer binding protein alpha; MTL CEBPA; sorafenib; unclassified drug; antineoplastic agent; CCAAT enhancer binding protein; CEBPA protein, human; liposome; nanoparticle; oligoribonucleotide; adult; aged; anemia; area under the curve; Article; ascites; clinical article; clinical outcome; cohort analysis; diarrhea; dizziness; drug distribution; drug dose escalation; drug efficacy; drug response; drug safety; drug withdrawal; dysgeusia; fatigue; female; fever; headache; hot flush; human; human cell; hyperbilirubinemia; hypertransaminasemia; hypoalbuminemia; hypophosphatemia; liver cell carcinoma; liver cirrhosis; liver metastasis; male; middle aged; minimum plasma concentration; multicenter study; multiple cycle treatment; nonalcoholic steatohepatitis; open study; phase 1 clinical trial; plasma clearance; plasma half life; priority journal; side effect; thrombocytopenia; upregulation; cancer staging; clinical trial; dose response; drug effect; gene expression regulation; genetics; intravenous drug administration; liver cell carcinoma; liver tumor; pathology; treatment outcome; tumor microenvironment; upregulation; very elderly; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Proteins; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Liposomes; Liver Neoplasms; Male; Middle Aged; Nanoparticles; Neoplasm Staging; Oligoribonucleotides; Treatment Outcome; Tumor Microenvironment; Up-Regulation |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。